IOBTQ 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2025-11-14

• On August 11, 2025, the Company issued a press release announcing topline results from our Phase 3 trial of Cylembio plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma. In the trial, Cylembio plus pembrolizumab demonstrated clinical improvement in PFS compared to pembro…

• The Company is supporting an investigator-initiated study (“IIT”) (NCT05912244) evaluating the combination of Cylembio plus nivolumab-relatlimab for the first-line treatment of patients with unresectable advanced melanoma at three study sites in the United States. The IIT has completed enrollment wi…

• On September 29, 2025, the Company issued a press release announcing that the FDA has recommended that the Company not

• submit a Biologics License Application (“BLA”) based on the data from the IOB-013 clinical trial. The Company has scheduled a meeting with the FDA in December 2025, to align on the design of a potential new registrational study for Cylembio® in patients with advanced melanoma and plans to discuss th…

• As part of the September press release, we also announced that the Company is implementing the Plan to conserve capital while it pursues a pathway to regulatory approval for Cylembio and works to complete ongoing studies. The Company is restructuring to reduce the Company’s ongoing expense structure…

相对上期删除的文字 · 来源:10-Q · 2025-08-14

• Our T-win platform is a novel approach to therapeutic cancer vaccines designed to activate pre-existing T cells to target immunosuppressive mechanisms. Our T-win product candidates are designed to employ a dual mechanism of action: (1) direct killing of immune-suppressive cells, including both tumor…

• contrast to previous methods that have sought to either block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells.

• We are developing a pipeline of product candidates that leverage our T-win® platform to address targets within the TME. In addition to melanoma, we are currently evaluating IO102-IO103 in multiple solid tumor indications. We are also focusing on additional targets that play key roles in immunosuppre…

• The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio® in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1…

• Improvement in PFS was achieved across virtually all subgroups, regardless of PD-L1 status, including those with poor prognostic factors, with a profound effect in PD-L1 negative patients treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=6…

相对上期新增的文字 · 来源:10-Q · 2025-11-14

• We have substantial doubt about our ability to continue as a going concern and the Company has been actively seeking, and continues to actively seek, additional capital to fulfill its operating and capital requirements. If additional capital is not available on a timely basis, or at all, the Company…

• We have substantial doubt about our ability to continue as a going concern and the Company has been actively seeking, and continues to actively seek, additional capital to fulfill its operating and capital requirements. If additional capital is not available on a timely basis, or at all, the Company…

• Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible no…

• The Company will require additional capital to develop and obtain regulatory approval for our lead candidate Cylembio®, and to continue to fund future discovery research, preclinical, clinical activities and commercialization of any of our product candidates. If we receive regulatory approval for Cy…

• We currently expect that our cash and cash equivalents of $30.7 million as of September 30, 2025, will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.

相对上期删除的文字 · 来源:10-Q · 2025-08-14

• We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not…

• · We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.

• We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not…

• Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates, especially immuno-oncology product candidates, is capital intensive. As our produ…

• We currently expect that our cash and cash equivalents of $28.1 million as of June 30, 2025, plus €12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expens…